teaser
Schering-Plough has announced that the US Food and Drug Administration has accepted the filing for review of the New Drug Application (NDA) for asenapine, a fast-dissolving, sublingual tablet.
The company is seeking marketing approval from the FDA for the treatment of schizophrenia and acute mania or mixed episodes associated with Bipolar Disorder.
↓Article continues below this sponsored advert↓
↑Advertisement↑
In accepting the NDA, the FDA indicated that asenapine would receive a standard review.
The clinical trial programme thus far has consisted of schizophrenia and bipolar mania trials involving nearly 3,000 patients.
Schering-Plough acquired asenapine through its combination with Organon BioSciences last week.
